MinorEstrogens – natural and semisynthetic×Antiepileptic with multiple mechanisms
Updated · Methodology
Mechanism
CYP3A4 partly metabolises estradiol (estradiol tablets label, US Food and Drug Administration, FDA). Drugs that induce cytochrome P450 enzymes, for example anticonvulsant barbiturates, phenytoin, primidone and carbamazepine, and possibly oxcarbazepine and topiramate, can speed up oestrogen metabolism and weaken the effect of oestrogens (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Zonisamide is not among these examples. According to its SmPC, it is not expected to change the levels of other drugs through cytochrome P450 enzymes and does not induce its own metabolism. In healthy volunteers, zonisamide did not change the levels of ethinylestradiol or norethisterone from a combined oral contraceptive (Zonegran SmPC, European Medicines Agency, EMA). CYP3A4 partly metabolises zonisamide itself, but the CYP3A4 inhibitors ketoconazole and cimetidine had no clinically relevant effect on its pharmacokinetics (Zonegran SmPC, EMA). The documents do not describe estradiol as an inhibitor or inducer of CYP3A4.
Symptoms
The documents describe no symptoms linked to this combination. Epilepsy can recur or worsen during estradiol treatment, and oestrogens can cause fluid retention, so women with epilepsy need careful observation during such treatment (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; estradiol tablets label, US Food and Drug Administration, FDA). The most frequent adverse effects of zonisamide added to other antiepileptic drugs are drowsiness, dizziness and loss of appetite. It can also cause metabolic acidosis, kidney stones and weight loss (Zonegran SmPC, European Medicines Agency, EMA).
Management
According to the documents, the doses of estradiol and zonisamide need no change. No document names the pair. Zonisamide is not among the enzyme inducers that speed up oestrogen metabolism, and in a study it did not change ethinylestradiol levels (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Zonegran SmPC, European Medicines Agency, EMA). Zonisamide is used for partial epileptic seizures. Epilepsy is on the list of conditions that need close supervision in women taking estradiol, because the disease can recur or worsen (Progynova SmPC, AEMPS). Use oestrogens with caution in women with epilepsy (estradiol tablets label, US Food and Drug Administration, FDA). If epilepsy worsens, reassess the benefits and risks of hormone replacement therapy and decide whether to continue it (Progynova SmPC, AEMPS). Estradiol given as hormone replacement therapy does not prevent pregnancy. When this therapy starts, stop hormonal contraception and, if contraception is still needed, switch to non-hormonal methods (Progynova SmPC, AEMPS). Women of childbearing potential need effective contraception throughout zonisamide treatment and for one month after it (Zonegran SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Estradiol (nº registro 47814), sección 4.5 (2026)– AEMPS, CIMA, nº registro 47814, revisión 02/2026, sección 4.5
- AEMPS: Ficha técnica: Estradiol, Progynova 1 mg (nº registro 47814), sección 4.4 (2026)– AEMPS, CIMA, nº registro 47814 (Progynova 1 mg comprimidos recubiertos, Bayer Hispania), revisión 02/2026, secciones 4.1, 4.4 y 4.5
- EMA: Ficha técnica: Zonisamida (EU/1/04/307), sección 4.5 (2026)– EMA, Zonegran 100 mg cápsulas duras (Amdipharm, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 04307004, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4, 4.5, 4.6, 4.8 y 5.2
- FDA: Estradiol tablets, Teva (estradiol) prescribing information (2024)– FDA, DailyMed setid c4936878-1643-4e7f-9b0d-e4957935aef2 (Teva Pharmaceuticals USA), revisión 02/2024 (versión 16), CLINICAL PHARMACOLOGY (Drug Interactions), PRECAUTIONS (Fluid retention, Exacerbation of other conditions)